Standard Contracts
Contract Year 1 - $[ * ] Contract Year 2 - $[ * ] Contract Year 3 - $[ * ] Contract Year 4 - $[ * ] Contract Year 5 - $[ * ]Distribution and License Agreement • July 21st, 2006 • Utix Group Inc • Services-amusement & recreation services
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING...Distribution and License Agreement • June 8th, 2015 • Rosewind CORP • Pharmaceutical preparations • New York
DISTRIBUTION AND LICENSE AGREEMENT BY AND BETWEEN GW PHARMA LTD AND NOVARTIS PHARMA AGDistribution and License Agreement • April 18th, 2013 • Gw Pharmaceuticals PLC • Pharmaceutical preparations • New York
This Distribution Agreement (“Agreement”) is entered into as of 8th April 2011 (“Effective Date”) by and between GW Pharma Ltd, a company incorporated under the laws of England and Wales (Company No. 03704998), whose registered office is at Porton Down Science Park, Wiltshire SP4 03Q (hereinafter referred to as “GW”) and Novartis Pharma AG, a company incorporated under the laws of Switzerland, with a place of business at Lichtstrasse 35, Basel, CH-4002 Switzerland, (hereinafter referred to as “Novartis”). GW and Novartis may hereinafter be referred to individually as a “Party” and collectively as the “Parties”.
DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • May 28th, 2020 • Gene Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS DISTRIBUTION AND LICENSE AGREEMENT (“Agreement”) dated as of April 10, 2020, is entered into between Angionetics Inc., a Delaware corporation having its principal place of business at 11568 Sorrento Valley Rd., Suite 14, San Diego, CA 92121 (“Angionetics”), a wholly-owned subsidiary of Gene Biotherapeutics, Inc., and Shanxi Taxus Pharmaceuticals Co., Ltd. (“Licensee”).
DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • May 8th, 2017 • Immuron LTD • Pharmaceutical preparations • Delaware
and all patents that derive priority from the same priority document and all other patents and patent applications in the same patent family, including all corresponding national phase filing, divisional application and continuations.
Distribution and License Agreement by and among Angiotech Pharmaceuticals, Inc. Angiotech International GmbH Cohesion Technologies, Inc. and Baxter Healthcare Corporation Baxter Healthcare, S. A.Distribution and License Agreement • March 16th, 2009 • Angiotech Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Distribution and License Agreement (“Distribution and License Agreement”), dated as of April 1, 2003 (“Effective Date”), is entered into by and among:
DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • September 30th, 2019 • Taronis Fuels, Inc. • Delaware
THIS Distribution and License Agreement, (hereinafter “Agreement”), dated the 16th day of July, 2019 is between Taronis Technologies, Inc., a Delaware Corporation, f/k/a MagneGas Applied Technology Solutions, Inc. and f/k/a MagneGas Corporation, and MAGNEGAS IP, LLC, a Delaware limited liability company (collectively, the “Company”); and Taronis Fuels, Inc., a Delaware Corporation (“Distributor”).
DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • March 8th, 2011 • Santarus Inc • Pharmaceutical preparations • New York
This DISTRIBUTION AND LICENSE AGREEMENT (this “Agreement”) is made as of September 3, 2010 (the “Effective Date”), by and among VeroScience, LLC, a Delaware limited liability company (“VeroScience”), S2 Therapeutics, Inc. f/k/a Wythe Therapeutics, Inc., a Tennessee corporation (“S2”), and Santarus, Inc., a Delaware corporation (“Santarus”). Each of VeroScience, S2 and Santarus is referred to herein individually as a “party” and collectively as the “parties.”
AMENDMENT NO. 2 TO DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • March 16th, 2009 • Angiotech Pharmaceuticals Inc • Pharmaceutical preparations
WHEREAS, Angiotech Pharmaceuticals, Inc., Angiotech International GmbH (now called Angiotech International AG) and Cohesion Technologies, Inc., on the one hand, and Baxter, on the other hand, previously executed a Distribution and License Agreement, effective as of April 1, 2003 (the “Original Agreement”);
AMENDMENT TO DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • December 14th, 2020 • Motorsport Gaming Us LLC • Services-prepackaged software • North Carolina
WHEREAS, 704Games Company, a Delaware corporation (“704GAMES” or “Licensee”), and NASCAR Team Properties, a series trust organized under the laws of Delaware (“NTP” or “Licensor”), entered into that certain Second Amended and Restated Distribution and License Agreement, effective as of January 1, 2019 (the “Distribution and License Agreement”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Distribution and License Agreement.
DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • March 12th, 2007 • Summer Infant, Inc. • Blank checks • Rhode Island
This Agreement is made in light of and in consideration of the following facts and circumstances that form a material part of this Agreement
DISTRIBUTION AND LICENCE AGREEMENTDistribution and License Agreement • April 19th, 2004 • Mtone Wireless Corp • Hong Kong
DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • August 17th, 2009 • Remote MDX Inc • Communications equipment, nec • New York
This Distribution and License Agreement (this “Agreement”) is made effective May 28, 2009 (the “Effective Date”) by and between RemoteMDx, Inc., a Utah corporation (“Licensor”), and euromicron AG, a German corporation (“Licensee”). Licensor and Licensee may be referred to herein as a “party” or together as the “parties.”
DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • November 23rd, 2016 • MyDx, Inc. • Measuring & controlling devices, nec • California
This DISTRIBUTION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into as of this 1st day of September 2016, by and between Powerfull Holdings, Ltd., a company operating under the charter of the People’s Republic of China, with its principal place of business located at 1209 Block A, Focal Industrial Centre, 21 Man Lok Street, Kowloon Hong Kong ("Licensee"), and MyDx, Inc., a Nevada Corporation, with its principal place of business located at 6335 Ferris Square Suite B, San Diego, CA 92121 ("Licensor"). Powerfull Holdings and Licensor are sometimes referred to herein individually as the “Party” or collectively as the “Parties.”
FIRST AMENDMENT TO DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • August 9th, 2004 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO DISTRIBUTION AND LICENSE AGREEMENT (the “Amendment”) is made and entered into on the 1st day of July, 2004 (the “Effective Date”), by and between NPS Allelix Corp. (“Licensor”), and Nycomed Danmark ApS (“Licensee”). Licensor and Licensee are referred to in this Amendment individually as a “Party” and collectively as the “Parties.”
DISTRIBUTION AND LICENSE AGREEMENT by and between MEDIZONE INTERNATIONAL, INC. and GYD S.A.Distribution and License Agreement • November 17th, 2015 • Medizone International Inc • Wholesale-drugs, proprietaries & druggists' sundries • Nevada
This Distribution and License Agreement (the “Agreement”), effective as of November 12, 2015 (the “Effective Date”), is entered into by Medizone International, Inc., a Nevada corporation, with its principal executive offices at 4000 Bridgeway, Suite 401, Sausalito, California 94965, USA (“Medizone”), and GYD S.A., a corporation formed under the laws of Chile, with its principal place of business at Los Cactus 1558 , Lo Barnechea , Santiago, Chile (“Distributor”).
Helsinn and Angelini Pharma sign a partnership agreement renewal to commercialize AULIN® and MESULID® in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak RepublicDistribution and License Agreement • June 5th, 2024
Lugano (Switzerland) and Rome (Italy)– May 27, 2024 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, and Angelini Pharma (“Angelini”), an international pharmaceutical company, part of the Italian privately-owned multi- business Angelini Industries, that researches, develops and commercializes health solutions with a focus on the areas of Brain Health, including Mental Health and Epilepsy, and Consumer Health, announce today the signing of the Distribution and Licence Agreement renewal in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic for AULIN® and MESULID® (Nimesulide) for the treatment of acute (short-term) pain.
AMENDMENT TO DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • June 16th, 2010 • Thermogenesis Corp • Laboratory apparatus & furniture
This Amendment effective as of June 14, 2010 (the “Amendment”) is made by and between Asahi Kasei Kuraray Medical Co., Ltd., a Japanese corporation (“ASAHI”) with an office and place of business at 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo 101-8101 Japan, and ThermoGenesis Corp., a Delaware corporation, (“THERMO”) with an office and place of business at 2711 Citrus Road, Rancho Cordova, California 95742, U.S.A., to the Distribution and License Agreement originally entered into effective as of the 28th day of March, 2005, by and between ASAHI and THERMO (the “Original Agreement”).
Nutri-Diem Montreal, June 26 2007 Mr. Jay Sargeant Essentially Yours Industries Inc. 3753 Howard Hughes Parkway, suite 200 Las Vegas, Nevada, United States 89145 OBJECT: Distribution and license agreement N/ref: 10 003-1 Mr. Sargeant, This letter...Distribution and License Agreement • July 9th, 2007 • Eyi Industries Inc. • Medicinal chemicals & botanical products
This letter concerns the distribution and license agreement (hereafter the "Agreement") entered between your company and Nutri-Diem Inc. (hereafter("Nutri-Diem") on June 30, 2002 as modified by an addendum on April 30, 2004.
DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • January 5th, 2017 • Magnegas Corp • Special industry machinery, nec • Florida
THIS DISTRIBUTION AND LICENSE AGREEMENT (this “Agreement”) is entered into this 30h day of December, 2016 by and between MAGNEGAS CORPORATION, a Delaware corporation (“MagneGas” or “LICENSOR”), with an address of 11885 44th St. North, Clearwater, FL 33762 and TALON VENTURES & CONSULTING GMBH, a company constituted under the laws of Germany (“LICENSEE” or “DISTRIBUTOR”), with an address of Stadtweg 7,D-30966 Hemmingen, Germany.
China Dongxiang (Group) Co., Ltd.Distribution and License Agreement • January 15th, 2019
This announcement is made on a voluntary basis by the board of directors (the ‘‘Board’’) of China Dongxiang (Group) Co., Ltd. (the ‘‘Company’’, together with its subsidiaries, the ‘‘Group’’) for providing updates on the business development of the Group.
ContractDistribution and License Agreement • November 9th, 2007 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances)
NOTE: CERTAIN CONFIDENTIAL INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT AND REPLACED BY “[*]”. A COMPLETE COPY OF THIS DOCUMENT INCLUDING THE CONFIDENTIAL INFORMATION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
ANY DISPUTE CONCERNING THIS CONTRACT IS SUBJECT TO MEDIATION AND ARBITRATION IN CHARLESTON, SOUTH CAROLINA, PURSUANT TO THE UNIFORM ARBITRATION ACT OF THE STATE OF SOUTH CAROLINA, SECTION 15-48-10 ET. SEQ. CODE OF LAWS OF SOUTH CAROLINA, 1976, AS AMENDED.Distribution and License Agreement • February 12th, 2016 • Fresh Healthy Vending International, Inc. • Refrigeration & service industry machinery • South Carolina
THIS AGREEMENT, dated this 8th day of February, 2016 (“Effective Date”), is entered into by and between ROBOFUSION, INC., a Delaware corporation, with its principal place of business located at 2300 Clements Ferry Road Suite 204, Charleston, South Carolina 29492 (“RFI”) and FRESH HEALTHY VENDING INTERNATIONAL, INC., a Nevada corporation,
FIRST AMENDMENT TO DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • May 5th, 2011 • Santarus Inc • Pharmaceutical preparations • New York
This FIRST AMENDMENT TO DISTRIBUTION AND LICENSE AGREEMENT (this “Amendment”) is made as of March 10, 2011 (the “Effective Date”), by and among VeroScience, LLC, a Delaware limited liability company (“VeroScience”), S2 Therapeutics, Inc. f/k/a Wythe Therapeutics, Inc., a Tennessee corporation (“S2”), and Santarus, Inc., a Delaware corporation (“Santarus”). Each of VeroScience, S2 and Santarus is referred to herein individually as a “party” and collectively as the “parties.”
1 EXHIBIT 10.1 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DISTRIBUTION...Distribution and License Agreement • August 13th, 1999 • Women First Healthcare Inc • Pharmaceutical preparations • New York
FIRST AMENDMENT TO DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • May 28th, 2020 • Gene Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
The undersigned, Angionetics Inc., a Delaware corporation (“Angionetics”) and a wholly-owned subsidiary of Gene Biotherapeutics, Inc., and Shanxi Taxus Pharmaceuticals Co., Ltd., a China-based company (“Licensee”), desire to amend, as of April 14, 2020, the Distribution and License Agreement, dated as of April 10, 2020 (the “D&L Agreement”). Capitalized terms used but not otherwise defined herein shall have the respective meanings set forth in the D&L Agreement.
WITNESSETH:Distribution and License Agreement • August 16th, 1999 • Cardiac Science Inc • Electromedical & electrotherapeutic apparatus
DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • December 2nd, 2005 • Xenoport Inc • Pharmaceutical preparations • New York
This Distribution and License Agreement (hereinafter, “Agreement”), is entered into and made effective as of the 1st day of December, 2005 (“Effective Date”), between XenoPort, Inc., a Delaware corporation having a place of business at 3410 Central Expressway, Santa Clara, CA 95051, United States of America (“XenoPort”), and Astellas Pharma Inc., a Japanese corporation having a place of business at 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 103-8411, Japan (“Astellas”). Each of XenoPort and Astellas shall be a “Party,” and together the “Parties.”
CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS ([***]) DENOTE SUCH OMISSIONS. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION.Distribution and License Agreement • April 14th, 2016 • Midatech Pharma PLC • Pharmaceutical preparations
THIS AGREEMENT (hereinafter called “Agreement”) is made and effective as of this 7th day of September 2012 (hereinafter called “Effective Date”), between HELSINN HEALTHCARE SA, a corporation organised and existing under the law of Switzerland and having its registered office at Via Pian Scairolo 9, 6912 Lugano, Switzerland (hereinafter called “HHC”) of the one part, and DARA BIOSCIENCES, INC., a corporation organised and existing under the law of North Carolina, USA, and having its registered office at 8601 Six Forks Road, Suite 160, Raleigh, NC 27615, United States of America (hereinafter called “DISTRIBUTOR”), of the other part.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. May 15, 2009Distribution and License Agreement • August 6th, 2009 • Xenoport Inc • Pharmaceutical preparations
This letter agreement (hereinafter, this “Amendment”) is to confirm the agreement between Astellas and XenoPort effective as of the 15th day of May, 2009 (the “Amendment Effective Date”), with respect to certain modifications to the Agreement as set out in Paragraphs 1 – 11 below. Each of XenoPort and Astellas shall be hereinafter referred to as a “Party,” and together as the “Parties.” Astellas and XenoPort agree that, effective the Amendment Effective Date, the Agreement shall be amended as follows:
DISTRIBUTION AND LICENSE AGREEMENT BY AND BETWEEN NPS ALLELIX CORP. NPS PHARMACEUTICALS, INC. AND NYCOMED GmbH DATED SEPTEMBER 24, 2007Distribution and License Agreement • November 9th, 2007 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Distribution and License Agreement (this “Agreement”) is made and effective as of the 24th day of September, 2007 (the “Effective Date”) by and between NPS Allelix Corp., a Canadian corporation (“NPS Allelix”), having offices at MaRS Centre, 101 College Street, South Tower, Suite 800, Toronto, ON MSG 1L8 Canada, NPS Pharmaceuticals, Inc., a Delaware corporation (“NPS US”, and, together with NPS Allelix, collectively, “NPS”), having offices at Morris Corporate Center 1, 4th Floor, Building B, 300 Interpace Parkway, Parsippany, NJ 07054, and Nycomed GmbH, a German corporation with company registration number Hrb Nr 701257 (“Nycomed”), having offices at Byk Gulden Str. 2, 78467 Konstanz.
DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • August 11th, 2009 • Activecare, Inc. • In vitro & in vivo diagnostic substances • New York
This Distribution and License Agreement (this “Agreement”) is made effective May 28, 2009 (the “Effective Date”) by and between Volu-Sol Reagents Corporation, a Utah corporation (“Licensor”), and euromicron AG, a German corporation (“Licensee”). Licensor and Licensee may be referred to herein as a “party” or together as the “parties.”
ASP SOFTWARE PRODUCTS DISTRIBUTION AND LICENSE AGREEMENT DATED for reference the 1st day of January 2001. BETWEEN: SIDEWARE INTERNATIONAL SRL, organized pursuant to the laws of Barbados, and having an office at 2nd Street, Holetown, St. James,...Distribution and License Agreement • March 23rd, 2001 • Sideware Systems Inc • Services-prepackaged software
1 EXHIBIT 10.14 LETTER AGREEMENT This Agreement, dated as of June 21, 1999, by and between WOMEN FIRST HEALTHCARE, INC., a Delaware corporation ("WFHC"), and LABORATOIRES FOURNIER S.A., a French corporation ("Fournier"). 1. Distribution and License...Distribution and License Agreement • June 24th, 1999 • Women First Healthcare Inc • Pharmaceutical preparations • New York
Amended and Restated Distribution and License Agreement by and among Angiotech Pharmaceuticals (US), Inc. Angiodevice International GmbH and Baxter Healthcare Corporation Baxter Healthcare, S. A.Distribution and License Agreement • May 8th, 2009 • Angiotech Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Amended and Restated Distribution and License Agreement (“Distribution and License Agreement”), dated as of January 1, 2009 (“Effective Date”), is entered into by and among:
